{{Rsnum
|rsid=5182
|Gene=AGTR1
|Chromosome=3
|position=148741608
|Orientation=plus
|GMAF=0.4747
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=AGTR1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 25.4 | 46.0 | 28.6
| HCB | 22.2 | 42.2 | 35.6
| JPT | 9.1 | 54.5 | 36.4
| YRI | 71.0 | 25.8 | 3.2
| ASW | 0.0 | 0.0 | 0.0
| CHB | 22.2 | 42.2 | 35.6
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}[[rs5182]] (573C/T) is a SNP within the [[AGTR1]] (Angiotensin II receptor type 1).

{{PMID|18347611}} among 4,096 hypertensive subjects, the CT/CC genotypes were associated with reduced risk of heart attack among those treated with [[ACE inhibitors]]

{{PharmGKB
|RSID=rs5182
|Name_s=AT1 573C>T
|Gene_s=AGTR1
|Feature=Exon/Syn
|Evidence=PubMed ID:20712529
|Annotation=Risk or phenotype-associated allele: T. Phenotype: Homozygotes for the minor allele (TT) had reduced HR for cardiac events while treated with perindopril. Study size: 8907. Study population/ethnicity: PERGENE study; EUROPA trial; European; White. Significance metric(s): p = 0.054. Type of association: CO
|Drugs=perindopril
|Drug Classes=ACE INHIBITORS, PLAIN
|Diseases=Coronary Artery Disease
|Curation Level=Curated
|PharmGKB Accession ID=PA165378308
}}

{{PharmGKB
|RSID=rs5182
|Name_s=AGTR1:rs5182
|Gene_s=AGTR1
|Feature=Exon/Syn
|Evidence=PubMed ID:17211857; PubMed ID:18049108
|Annotation=Associated with a decrease in eGFR; no difference in mRNA expression observed.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161145030
}}

{{PharmGKB
|RSID=rs5182
|Name_s=AGTR1: 573C/T; 573C>T
|Gene_s=AGTR1
|Feature=Exon/Syn
|Evidence=PubMed ID:18347611
|Annotation=The C allele carriers tend to have reduced risk of myocardial infarction in patients taking ACE inhibitors.
|Drugs=captopril; enalapril; fosinopril; imidapril; lisinopril
|Drug Classes=ACE INHIBITORS, PLAIN
|Diseases=Hypertension; Myocardial Infarction; Stroke
|Curation Level=Curated
|PharmGKB Accession ID=PA162369932
}}

{{PMID Auto
|PMID=21671168
|Title=Association of polymorphisms in angiotensin II receptor genes with aldosterone-producing adenoma
}}

{{PMID Auto
|PMID=22508051
|Title=Renin-Angiotensin-aldosterone system gene polymorphisms and coronary artery disease: detection of gene-gene and gene-environment interactions
}}

{{PMID Auto
|PMID=21846682
|Title=Association of angiotensin II type 1-receptor gene polymorphisms with the risk of developing hypertension in Mexican individuals.
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs5182
|overall_frequency_n=4031
|overall_frequency_d=10758
|overall_frequency=0.374698
|n_genomes=36
|n_genomes_annotated=0
|n_haplomes=46
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=24622918
|Title=Renin-Angiotensin System Genetic Polymorphisms and Brain White Matter Lesions in Older Australians
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}